Sample size formulae for two-stage randomized trials with survival outcomes.

Two-stage randomized trials are growing in importance in developing adaptive treatment strategies, i.e. treatment policies or dynamic treatment regimes. Usually, the first stage involves randomization to one of the several initial treatments. The second stage of treatment begins when an early nonresponse criterion or response criterion is met. In the second-stage, nonresponding subjects are re-randomized among second-stage treatments. Sample size calculations for planning these two-stage randomized trials with failure time outcomes are challenging because the variances of common test statistics depend in a complex manner on the joint distribution of time to the early nonresponse criterion or response criterion and the primary failure time outcome. We produce simple, albeit conservative, sample size formulae by using upper bounds on the variances. The resulting formulae only require the working assumptions needed to size a standard single-stage randomized trial and, in common settings, are only mildly conservative. These sample size formulae are based on either a weighted Kaplan-Meier estimator of survival probabilities at a fixed time-point or a weighted version of the log-rank test.

[1]  P. Holland.  Statistics and Causal Inference , 1985 .

[2]  J. Robins.  Addendum to “a new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect” , 1987 .

[3]  James R McKay,et al.  Adaptive Interventions in Drug Court , 2008, Criminal justice review.

[4]  A. Wahed,et al.  Weighted Kaplan–Meier estimators for two‐stage treatment regimes , 2010, Statistics in medicine.

[5]  Anastasios A. Tsiatis,et al.  Semiparametric efficient estimation of survival distributions in two-stage randomisation designs in clinical trials with censored data , 2006 .

[6]  R. Nelsen.  An Introduction to Copulas , 1998 .

[7]  Alena I. Oetting,et al.  Statistical Methodology for a SMART Design in the Development of Adaptive Treatment Strategies , 2011 .

[8]  J. Robins,et al.  Estimation of Regression Coefficients When Some Regressors are not Always Observed , 1994 .

[9]  S. Murphy,et al.  Developing adaptive treatment strategies in substance abuse research. , 2007, Drug and alcohol dependence.

[10]  Bill Ravens,et al.  An Introduction to Copulas , 2000, Technometrics.

[11]  Stephen L. George,et al.  Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia , 1995 .

[12]  K. Lynch,et al.  The effectiveness of telephone-based continuing care in the clinical management of alcohol and cocaine use disorders: 12-month outcomes. , 2004, Journal of consulting and clinical psychology.

[13]  R. Peto,et al.  Asymptotically efficient rank invariant test procedure (with discussion). , 1972 .

[14]  D. Schoenfeld.  The asymptotic properties of nonparametric tests for comparing survival distributions , 1981 .

[15]  S. Chow,et al.  Sample Size Calculations In Clinical Research , 2007 .

[16]  M. Kosorok,et al.  A Sample Size Formula for the Supremum Log‐Rank Statistic , 2005, Biometrics.

[17]  Ree Dawson,et al.  Dynamic treatment regimes: practical design considerations , 2004, Clinical trials.

[18]  P. Shrout,et al.  Causality and Psychopathology: Finding the Determinants of Disorders and their Cures , 2010 .

[19]  J. Robins.  A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect , 1986 .

[20]  J. Robins.  Errata to “a new approach to causal intefence in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect” Mathl Modelling 7(9–12), 1393–1512 (1986) , 1987 .

[21]  Abdus S Wahed,et al.  Sample size for two‐stage studies with maintenance therapy , 2009, Statistics in medicine.

[22]  Anne Lohrli.  Chapman and Hall , 1985 .

[23]  D. Kupfer,et al.  Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. , 2004, Controlled clinical trials.

[24]  Yuliya Lokhnygina,et al.  Cox Regression Methods for Two‐Stage Randomization Designs , 2007, Biometrics.

[25]  S. Murphy,et al.  An experimental design for the development of adaptive treatment strategies , 2005, Statistics in medicine.

[26]  Marie Davidian,et al.  Estimation of Survival Distributions of Treatment Policies in Two‐Stage Randomization Designs in Clinical Trials , 2002, Biometrics.

[27]  J M Robins,et al.  Marginal Mean Models for Dynamic Regimes , 2001, Journal of the American Statistical Association.

[28]  R. Cellerino,et al.  A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV‐E) or teniposide (CAV‐T), followed by recombinant interferon‐α maintenance therapy or observation, in small cell lung carcinoma patients with complete responses , 1997, Cancer.

[29]  James M. Robins,et al.  Causal Inference from Complex Longitudinal Data , 1997 .

[30]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[31]  Vijay N. Nair,et al.  A strategy for optimizing and evaluating behavioral interventions , 2005, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[32]  Ree Dawson,et al.  Flexible treatment strategies in chronic disease: clinical and research implications , 2000, Biological Psychiatry.

[33]  Guo Xiang,et al.  A Weighted Risk Set Estimator for Survival Distributions in Two-Stage Randomization Designs with Censored Survival Data , 2005 .

[34]  A. Wahed,et al.  Supremum weighted log-rank test and sample size for comparing two-stage adaptive treatment strategies , 2008 .